scorecardresearch
Centre denies permission to SII to conduct Covavax trials on children

Centre denies permission to SII to conduct Covavax trials on children

The central government on Thursday recommended against allowing Serum Institute of India to conduct phase 2 and 3 clinical trials of Covavax COVID-19 vaccine for the age group 2-17 years.

advertisement
iNDIA iNDIA

NEW DELHI: The central government on Thursday recommended against allowing Serum Institute of India to conduct phase 2 and 3 clinical trials of Covavax COVID-19 vaccine for the age group 2-17 years.

The government instructed SII to complete the trials on adults first.

As children are more likely to be affected by the third wave of COVID-19, vaccines for them has become the need of the hour.

Also Read:  Breaking: NIA court discharges Akhil Gogoi from remaining Chandmari case

Reportedly the centre recommended that "the Pune-based company should submit the safety and immunogenicity data (of Covovax) from the ongoing clinical trial in adults for considering the conduct of a clinical trial in children," as stated in a report.

SII had sought permission from Drug Controller General of India to test the vaccine on children.

Earlier, the Centre said that Novavax COVID vaccine efficacy data in a large trial are promising.

Also the clinical trials are being conducted and are in an advanced stage of completion in India.

Follow us on Facebook